Drug Information

Drug General Information
Drug ID
D0J1VB
Former ID
DNC010251
Drug Name
4-(piperazin-1-yl)thieno[3,2-c]pyridine
Drug Type
Small molecular drug
Indication Discovery agent Investigative [530516]
Formula
C11H13N3S
Canonical SMILES
C1CN(CCN1)C2=NC=CC3=C2C=CS3
InChI
1S/C11H13N3S/c1-3-13-11(9-2-8-15-10(1)9)14-6-4-12-5-7-14/h1-3,8,12H,4-7H2
InChIKey
RVGRTFBJOXMFAX-UHFFFAOYSA-N
PubChem Compound ID
10966027
Target and Pathway
Target(s) 5-hydroxytryptamine 2C receptor Target Info Inhibitor [530516]
KEGG Pathway Calcium signaling pathway
Neuroactive ligand-receptor interaction
Gap junction
Serotonergic synapse
Inflammatory mediator regulation of TRP channels
PANTHER Pathway 5HT2 type receptor mediated signaling pathway
Reactome Serotonin receptors
G alpha (q) signalling events
WikiPathways Serotonin Receptor 2 and ELK-SRF/GATA4 signaling
Monoamine GPCRs
GPCRs, Class A Rhodopsin-like
Gastrin-CREB signalling pathway via PKC and MAPK
GPCR ligand binding
GPCR downstream signaling
References
Ref 530516Bioorg Med Chem Lett. 2010 Jan 1;20(1):266-71. Epub 2009 Oct 30.Design and synthesis of orally-active and selective azaindane 5HT2c agonist for the treatment of obesity.
Ref 530516Bioorg Med Chem Lett. 2010 Jan 1;20(1):266-71. Epub 2009 Oct 30.Design and synthesis of orally-active and selective azaindane 5HT2c agonist for the treatment of obesity.